Apnimed, Inc. (APMD)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	120.15M +380.1%
Net Income	-31.83M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About APMD

Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improvin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: APMD
• Website: https://apnimed.com/

Financial Performance

Financial numbers in USD

Data Source: SEC filings Last updated: Jul 11, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error